Securities code: 300497 securities abbreviation: Jiangxi Fushine Pharmaceutical Co.Ltd(300497) Announcement No.: 2022-002
Jiangxi Fushine Pharmaceutical Co.Ltd(300497)
Announcement on resolutions of the 27th meeting of the third board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 27th meeting of the third board of directors of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (hereinafter referred to as “the company”)
All directors shall be notified by e-mail on January 4, 2022, and on site and on January 6, 2022
By means of communication. There were 9 directors who should attend the meeting, and 9 directors actually attended the meeting. The meeting was presided over by Chairman Bao Jianhua. The convening and voting procedures of the meeting comply with the company law of the people’s Republic of China and other laws and regulations and the relevant provisions of the articles of association, and are legal and effective. After deliberation by the attending directors, the following resolutions are adopted:
1、 The proposal on changing the use of funds raised by issuing some shares to specific objects and adding projects raised for investment was deliberated and adopted
On the premise of comprehensively considering the company’s overall development strategy and capacity layout, in order to ensure the efficient use of raised funds,
The changed part of the company issues shares to specific objects to raise funds for the construction of “annual output of 10000 tons of VC and 2000 tons of VC”
FEC project “.
The change of the purpose of some raised funds is in line with the company’s development strategy and long-term plan. The construction of the new raised investment project is a prudent decision based on the company’s experience in the field of chemical synthesis for many years, its advantages in safety, environmental protection and production management, combined with the opportunity of the rapid development of the new energy lithium battery industry, in order to comply with the industrial development trend, meet the market demand and expand the company’s product varieties. After the project is put into operation, it will further enhance the profitability and anti risk ability of the company and provide a strong guarantee for the long-term and steady development of the company. Purpose of some raised funds
The change does not harm the interests of shareholders of the company, especially the interests of minority shareholders. See http / / www.cninfo.com for details（ http://www.cn.info.com..cn. ）。
The independent directors of the company expressed their independent opinions on this matter.
Voting results: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
2、 The proposal on the appointment of deputy general manager of the company was deliberated and adopted
Due to the needs of the company’s operation and development, Mr. Wei Haipeng was appointed as the deputy general manager of the company in accordance with the company law, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and other relevant provisions, nominated by the general manager of the company and reviewed and approved by the nomination committee of the board of directors, The term of office starts from the date of deliberation and approval of the current board of directors to the date of expiration of the term of office of the third board of directors.
The independent directors of the company expressed their independent opinions on this matter.
Voting results: 9 in favor, 0 against and 0 abstention.
3、 Deliberated and adopted the on changing business scope and revising
<公司章程>
Proposal for
According to the actual business situation of the company, it is necessary to adjust the business scope of the company and revise the corresponding provisions of the articles of association. See http / / www.cninfo.com for details（ http://www.cn.info.com..cn. ）。
Voting results: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
4、 The notice on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
The company will hold the first extraordinary general meeting of shareholders in 2022 at 14:30 on January 24, 2022 in the company’s conference room. The general meeting of shareholders is held by combining on-site voting and online voting. See http://www.cninfo.com.cn for details（ http://www.cn.info.com..cn. ）。
Voting results: 9 in favor, 0 against and 0 abstention. It is hereby announced.
Jiangxi Fushine Pharmaceutical Co.Ltd(300497) board of directors
January 6, 2022
